Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long‐term lamivudine therapy
Jung Woo Shin(Ulsan College), Dong Jin Suh(Daehang Hospital), Han Chu Lee(Asan Medical Center), In‐Sook Kim(Frederick National Laboratory for Cancer Research), Myoung Kuk Jang, Neung Hwa Park(Ulsan College), Jeong‐Ah Kim(Ulsan College), Soo Hyung Ryu(Ulsan College), YOUNG‐HWA CHUNG(Ulsan College), Yung Sang Lee(The University of Texas at Dallas), M.H. Choi(Ulsan College)
Cited by 13
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
|Carcinogenesis|2006|359